2700303-28-0
Chemical Structure
S217879
- CAS No.: 2700303-28-0
- Formula:C30H32N4O7S
- Molecular Weight:592.66
InChIKey: CAHCZMVBPKUGCY-IBVKSMDESA-N
SMILES: CC1=CC=C(C=C1[C@H](N2C3)C)[C@H](CC(O)=O)C4=CC=C5C(N=NN5CCOCCOC6=CC3=C(OS2(=O)=O)C=C6)=C4C
Biological Activity: S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (Kd: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
S217879 | S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (Kd: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Seedorf K, et al. Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice. JHEP Rep. 2022;5(4):100651. Published 2022 Dec 16. [Content Brief]
- [2]. Wang Y, et al. cGAS-STING Targeting Offers Novel Therapeutic Opportunities in Liver Diseases. Drug Des Devel Ther. 2025;19:5835-5853. Published 2025 Jul 9. [Content Brief]
Keywords
